Moncada, Silvia; Allen, Bryce; Hafen, Tanner; Valencia-Amores, Sebastian; Hanson, Luke; Dorian, Sariah; Bechtel, Matth;ew; Smith, Seth; Myres, Isaac; Holding, Clayton; Jacobs, Dallin; Hellwig, Lexi; White, Joshua; Evanson, Davin; Cheney, Cladin; Taylor, Sloan; Grossman, Jesse; Donaldson, Jesse; Jepsen, Emily; Johnston, Maren; Porter, Kaiden; Jardine, Alyson; Garfield, Seth; Larson, Spencer; Gardiner (Brigham Young University)
Faculty Advisor: Mizrachi, Dario (College of Life Sciences, Physiology & Molecular Biology)
Heart disease is the leading cause of death in the United States. During myocardial infarction cardiac tissue suffers a lack of nutrients and oxygen that leads to the formation of unregenerable scar tissue which causes a loss of myocardial functionality. With the advent of human induced pluripotent stem cells (hiPSC), the promise of engineering autologous cardiac tissues (ECTs) as a translatable treatment to cardiac disease and as a model for pharmaceutical research is ever closer. We create ECTs using iPS-human induced cardiomyocytes (hiCMs) and extra cellular matrix (ECM) derived from a decellularized left ventricle of a porcine heart. Decellularized matrices allow the preservation of important architectural cues found in the native heart for hiCMs development (Momtahan, 2015). Nevertheless, ECTs still face some challenges before they can be useful in a clinical or pharmaceutical research setting i.e. poor ECT contractile force, hiCM maturity, proper cell morphology and architecture, etc. (Dwenger, 2018). In this study, we seek to combine the mechanical cues of the preserved architecture of a decellularized matrix with the spatiotemporal accuracy of optogenetics as a novel technique to stimulate ECT functionality assessed through contractile force, proper hiCM elongation, and alignment.